Phaseline

Companies › Tcelltech

Tcelltech: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TX103
Anti-B7-H3 chimeric antigen receptor T-cell (CAR-T cell) therapy
B7H3Phase 1High-grade Glioma; Solid TumorsJun 2027
DIT309
CAR-T cell therapy
–Phase 1OsteosarcomaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06482905TX103Phase 1High-grade GliomaOncologyJun 2027
NCT07052383DIT309Phase 1OsteosarcomaOncologyOct 2027
NCT07231081TX103Phase 1Solid TumorsOncologyDec 2027

Targets

B7H3 (1)

Companies with the same targets

BioNTech SE Hansoh BioMedical R&D Company Daiichi Sankyo Qilu Pharmaceutical IDEAYA Biosciences MediLink Therapeutics (Suzhou) CSPC Megalith Biopharmaceutical Phrontline Biopharma Aktis Oncology NEOK Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.